Porst Theresa, Johannes Jörg, Gluschke Hans, Köhler Richard, Mehl Sebastian, Kühnen Peter, Renko Kostja, Minich Waldemar B, Wiegand Susanna, Schomburg Lutz
Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, D-10115 Berlin, Germany.
Department of Paediatric Endocrinology and Diabetology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, D-13353 Berlin, Germany.
Biomedicines. 2021 Apr 30;9(5):496. doi: 10.3390/biomedicines9050496.
The monocarboxylate transporters 8 (MCT8) and 10 (MCT10) are important for thyroid hormone (TH) uptake and signaling. Reduced TH activity is associated with impaired development, weight gain and discomfort. We hypothesized that autoantibodies (aAb) to MCT8 or MCT10 are prevalent in thyroid disease and obesity. Analytical tests for MCT8-aAb and MCT10-aAb were developed and characterized with commercial antiserum. Serum samples from healthy controls, thyroid patients and young overweight subjects were analyzed, and prevalence of the aAb was compared. MCT8-aAb were additionally tested for biological effects on thyroid hormone uptake in cell culture. Positive MCT8-aAb and MCT10-aAb were detected in all three clinical cohorts analyzed. MCT8-aAb were most prevalent in thyroid patients (11.9%) as compared to healthy controls (3.8%) and overweight adolescents (4.2%). MCT8-aAb positive serum reduced T4 uptake in cell culture in comparison to MCT8-aAb negative control serum. Prevalence of MCT10-aAb was highest in the group of thyroid patients as compared to healthy subjects or overweight adolescents (9.0% versus 4.5% and 6.3%, respectively). We conclude that MCT8 and MCT10 represent autoantigens in humans, and that MCT8-aAb may interfere with regular TH uptake and signaling. The increased prevalence of MCT8-aAb and MCT10-aAb in thyroid disease suggests that their presence may be of pathophysiological relevance. This hypothesis deserves an analysis in large prospective studies.
单羧酸转运蛋白8(MCT8)和10(MCT10)对甲状腺激素(TH)的摄取和信号传导至关重要。甲状腺激素活性降低与发育受损、体重增加和不适有关。我们推测,针对MCT8或MCT10的自身抗体(aAb)在甲状腺疾病和肥胖症中普遍存在。我们利用商业抗血清开发并鉴定了针对MCT8-aAb和MCT10-aAb的分析检测方法。分析了来自健康对照、甲状腺疾病患者和年轻超重受试者的血清样本,并比较了自身抗体的流行率。此外,还在细胞培养中测试了MCT8-aAb对甲状腺激素摄取的生物学效应。在所有三个分析的临床队列中均检测到阳性的MCT8-aAb和MCT10-aAb。与健康对照(3.8%)和超重青少年(4.2%)相比,MCT8-aAb在甲状腺疾病患者中最为普遍(11.9%)。与MCT8-aAb阴性对照血清相比,MCT8-aAb阳性血清在细胞培养中降低了T4摄取。与健康受试者或超重青少年相比,MCT10-aAb的流行率在甲状腺疾病患者组中最高(分别为9.0%、4.5%和6.3%)。我们得出结论,MCT8和MCT10是人类自身抗原,MCT8-aAb可能会干扰甲状腺激素的正常摄取和信号传导。甲状腺疾病中MCT8-aAb和MCT10-aAb流行率的增加表明它们的存在可能具有病理生理学意义。这一假设值得在大型前瞻性研究中进行分析。